|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.02 CNY | +3.08% |
|
+2.87% | -33.16% |
| Mar. 18 | Hainan Shuangcheng Pharma's Unit Gets Green Light to Market Pregabalin Capsules | MT |
| Mar. 15 | Shuangcheng Pharmaceutical Gets Nod to Market Anticoagulant in Saudi Arabia | MT |
Hainan Shuangcheng Pharmaceuticals Co., Ltd. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 126.81 million compared to CNY 173.66 million a year ago. Net loss was CNY 1.81 million compared to net income of CNY 6 million a year ago.
Basic loss per share from continuing operations was CNY 0.0045. Diluted loss per share from continuing operations was CNY 0.0045.
| 1st Jan change | Capi. | |
|---|---|---|
| -33.16% | 289M | |
| +20.44% | 21.89B | |
| +8.31% | 14.45B | |
| +13.07% | 13.63B | |
| +37.46% | 11.49B | |
| -8.59% | 6.85B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.35% | 5.06B | |
| -5.36% | 4.66B |
HAINAN SHUANGCHENG PHARMACEUTICALS CO., LTD. 
